WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of
sustained release, drug delivery products for treating eye diseases,
today announced that its financial results for the first quarter of
fiscal year 2015 will be released before the market open on Friday,
November 7, 2014. A conference call and live webcast is scheduled for
8:30 a.m. ET that morning.
The conference call may be accessed by dialing (877) 312-7507 from the
U.S. and Canada, or (631) 813-4828 from international locations. A live
webcast will be available on the Investor Relations section of the
corporate website at http://www.psivida.com.
A replay of the call will be available beginning November 7, 2014, at
approximately 11:30 a.m. ET and ending on November 14, 2014, at 11:59
p.m. ET. The replay may be accessed by dialing (855) 859-2056 within the
U.S. and Canada or (404) 537-3406 from international locations,
Conference ID Number: 30044979. A replay of the webcast will also be
available on the corporate website during that time.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, is a leader in the
development of sustained release, drug delivery products for treating
eye diseases. pSivida is currently focused on treatment of chronic
diseases of the back of the eye utilizing its core technology systems,
Durasert™ and Tethadur™. pSivida's lead product candidate, Medidur™ for
treatment of the chronic, back-of-the-eye disease posterior uveitis, is
in a pivotal Phase III clinical trial. Medidur uses the same injectable,
sustained release micro-insert as ILUVIEN® for the treatment of DME.
ILUVIEN, licensed to Alimera Sciences, is marketed in the U.K. and
Germany and has received or is pending marketing authorization in 15
other EU countries for the treatment of chronic DME considered
insufficiently responsive to available therapies. In the U.S., ILUVIEN
has been approved for the treatment of DME in patients who have been
previously treated with a course of corticosteroids and did not have a
clinically significant rise in intraocular pressure. pSivida's
FDA-approved Retisert®, an implant that provides long-term, sustained
drug delivery to treat posterior uveitis, is licensed to and sold by
Bausch & Lomb Incorporated. pSivida's pre-clinical research is focused
on ocular and systemic delivery of biologics and treatment of wet and
dry age-related macular degeneration, osteoarthritis and glaucoma.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. The following are
some of the factors that could cause actual results to differ materially
from the anticipated results or other expectations expressed,
anticipated or implied in our forward-looking statements: changes in
actual capital requirements to 2017; Alimera's ability to finance,
achieve additional marketing approvals, obtain adequate pricing and
reimbursement for, successfully commercialize and achieve market
acceptance of, and generate revenues to pSivida from, ILUVIEN; FDA
requirements with respect to clinical trial data necessary to support an
NDA for Medidur; pSivida's ability to finance, complete and achieve a
successful clinical outcome, file and achieve marketing approvals for,
Medidur for posterior uveitis; ability of Tethadur to successfully
deliver large biologic molecules; ability to develop product candidates
and products and potential related collaborations; initiation and
completion of clinical trials and obtaining regulatory approval of
product candidates; level of continued sales of Retisert; adverse side
effects; ability to attain profitability; ability to obtain additional
capital; further impairment of intangible assets; fluctuations in
operating results; decline in royalty income; ability to, and to find
partners to, develop and market products; termination of license
agreements; competition and other developments affecting sales of
products; market acceptance; protection of intellectual property and
avoiding intellectual property infringement; retention of key personnel;
product liability; consolidation in the pharmaceutical and biotechnology
industries; compliance with environmental laws; manufacturing risks;
risks and costs of international business operations; credit and
financial market conditions; legislative or regulatory changes;
volatility of stock price; possible dilution; absence of dividends; and
other factors described in our filings with the SEC. Given these
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Should known or unknown risks materialize,
or should underlying assumptions prove inaccurate, actual results could
differ materially from past results and those anticipated, estimated or
projected in the forward-looking statements. Our forward-looking
statements speak only as of the dates on which they are made. We do not
undertake any obligation to publicly update or revise our
forward-looking statements even if experience or future changes makes it
clear that any projected results expressed or implied in such statements
will not be realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog: http://www.thechairmansblog.com/paul-ashton
For more information on pSivida, visit www.psivida.com.
In US:
Martin E. Janis & Company, Inc.
Beverly
Jedynak
President
+1 312 943 1123
M: +1 773 350 5793
bjedynak@janispr.com
Source: pSivida Corp.
News Provided by Acquire Media
